Please use this identifier to cite or link to this item:
Title: Cancer Drugs Fund requires further reform.
Authors: Grieve, Richard
Abrams, Keith
Claxton, Karl
Goldacre, Ben
James, Nicholas
Nicholl, Jon
Parmar, Mahesh
Parker, Chris
Sekhon, Jasjeet S.
Smeeth, Liam
Spiegelhalter, David
Sculpher, Mark
First Published: 27-Sep-2016
Publisher: BMJ Publishing Group
Citation: BMJ, 2016, 354
Abstract: [First paragraph] The reforms to the Cancer Drugs Fund implemented in July were an excellent opportunity to generate evidence on the effectiveness of new cancer drugs.1 Unlike under the previous arrangements, data on patients’ outcomes will have to be collected for all drugs funded by the scheme. However, the reforms’ stated reliance on “real world” (observational) data will not generate reliable evidence of effectiveness. We propose an alternative model, using timely randomised controlled trials within routinely collected data sources, to establish which drugs are relatively effective. The current arrangement encourages early access to drugs, with high prices but uncertain benefits, whereas our proposal will provide high quality evidence for future decisions and therefore larger gains in population health.
DOI Link: 10.1136/bmj.i5090
ISSN: 0959-8138
eISSN: 1756-1833
Version: Publisher Version
Status: Peer-reviewed
Type: Journal Article
Rights: Copyright © 2016, BMJ. Deposited with reference to the publisher’s open access archiving policy. (
Appears in Collections:Published Articles, Dept. of Health Sciences

Files in This Item:
File Description SizeFormat 
bmj.i5090.full.pdfPublished (publisher PDF)496.83 kBAdobe PDFView/Open

Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.